Alpelisib for treating severe PIK3CA-related overgrowth spectrum in people 2 years and over [ID6252]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Baricitinib for treating severe or very severe alopecia areata in people 6 to 17 years [ID6541]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Children and young people with disabilities and severe complex needs: integrated health and social care supportStatus:Awaiting developmentExpected publication date: TBC
CM-AT for behaviours associated with autism in children and young people [ID6731]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Delandistrogene moxeparvovec for treating Duchenne muscular dystrophy in children 4 to 7 years [ID3897]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Etavopivat for treating sickle cell disease in people 12 years and over [ID6698]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Fenfluramine for treating seizures caused by CDKL5 deficiency disorder in people 1 year and over [ID6740]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Inclisiran for treating familial hypercholesterolaemia and elevated low density lipoprotein cholesterol in people 12 to 17 years [TSID12129]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Infant, children and young people's experience of health careStatus:Awaiting developmentExpected publication date: TBC
Ixekizumab for treating enthesitis-related arthritis and juvenile psoriatic arthritis in people 2 to 17 years [ID6590]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Leriglitazone for treating X-linked andrenoleukodystrophy [TSID9996]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Liposomal cytarabine–daunorubicin for treating relapsed or refractory acute myeloid leukaemia in people aged 1 to 21 years [ID4017]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Navepegritide for treating achondroplasia in people 2 to 15 years [ID6538]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Naxitamab with GM-CSF for treating relapsed or refractory high-risk neuroblastoma [ID3769]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Odevixibat for treating biliary atresia in children following Kasai hepatoportoenterostomy [ID6627]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Pariglasgene brecaparvovec for treating glycogen storage disease type 1a in people 8 years and over [TSID11865]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Perampanel for adjunctive treatment of partial onset or generalised tonic-clonic seizures in children aged below 12 years with epilepsy [ID1587]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Remibrutinib for treating chronic spontaneous urticaria inadequately controlled by H1-antihistamines in people 12 to 17 years [ID6649]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Ruxolitinib for treating acute graft-versus-host disease after allogeneic stem cell transplant in people 28 days to 17 years [ID6410]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Somapacitan for treating growth failure caused by Turner syndrome in people 2 to 17 years [ID6621]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Tideglusib for treating congenital or childhood onset myotonic dystrophy [ID3915]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Tirzepatide for managing overweight and obesity in people 12 to 17 years [ID6707]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Tirzepatide for treating type 2 diabetes in people 10 to 17 years [ID6539]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Topical tapinarof for treating atopic dermatitis in people 2 years and over [ID6713]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Vosoritide for treating achondroplasia in children and young people under 18 years [ID3807]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC